NASDAQ:OKYO

OKYO Pharma Ltd

Market:

NASDAQ

Price

1.52 USD

Day Change

-0.65%

Market Cap:

$79.77 m

52 weeks high

3.34

52 weeks low

1.35

04.52

Executive Interviews

In brief

OKYO Pharma Ltd. is an emerging clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases.

The company is committed to addressing significant unmet medical needs through innovative science, targeted therapeutic approaches, and a disciplined clinical and regulatory development strategy.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

OKYO Pharma has dry eyes as a lucrative prize in its sights

Okyo Pharma Limited -

Snapshot

OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025

Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025

on 03/21/2025

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases

on 12/23/2024

AbbVie acquisition signals confidence in small-cap biotech sector’s growth potential

on 03/26/2024

GSK, Merck deals show appetite is ripe for biopharmaceutical M&A

on 04/18/2023

Are small-cap biotech stocks good investments now?

on 08/14/2020

Watch

OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain

Executive Interviews OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain

4 weeks, 2 days ago

OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment

Executive Interviews OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment

on 05/19/2026

OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial

Executive Interviews OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial

on 01/28/2026

OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO

Executive Interviews OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO

on 01/05/2026